# CITYSCAPE (NCT03563716)

> A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03563716
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Non-small Cell Lung Cancer
- Interventions: Atezolizumab; Tiragolumab; Placebo
- Enrollment: 135
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on CITYSCAPE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 7
- Podcasts: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cityscape-nct03563716

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03563716", "email": "<work email>"}; the inbox owner confirms by the emailed link.